Get the Stockscreener App
2.01
5.24%
0.10
After Hours:
1.98
-0.03
-1.49%
Prokidney Corp stock is traded at $2.01, with a volume of 2.82M.
It is up +5.24% in the last 24 hours and down -10.67% over the past month.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$1.91
Open:
$1.93
24h Volume:
2.82M
Relative Volume:
3.07
Market Cap:
$285.31M
Revenue:
$893.00K
Net Income/Loss:
$-151.61M
P/E Ratio:
-3.9014
EPS:
-0.5152
Net Cash Flow:
$-135.31M
1W Performance:
+8.65%
1M Performance:
-10.67%
6M Performance:
-36.59%
1Y Performance:
+183.06%
1-Day Range:
$1.92
$2.035
1-Week Range:
$1.835
$2.035
52-Week Range:
$0.54
$7.13
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
2.01 | 271.11M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney (NASDAQ:PROK) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Bull Run: Can ProKidney Corp continue delivering strong returns2026 Key Highlights & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Winners Losers: Is ProKidney Corp impacted by rising rates2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
High stakes: ProKidney pushes toward commercialization as cash dwindles, opportunity awaits - The Business Journals
Analysis Recap: Will ProKidney Corp benefit from government policyQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
April 2026 Penny Stock Highlights - Sahm
Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK - MarketBeat
Analysis Recap: What is the long term forecast for ProKidney Corp stockTrade Performance Summary & Low Drawdown Trading Strategies - baoquankhu1.vn
What Makes ProKidney Corp. (PROK) So Attractive - Yahoo Finance
Sell Signal: Will ProKidney Corp benefit from geopolitical trendsTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Revenue Check: Does ProKidney Corp outperform in volatile markets2026 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Shares Up 5.9%Here's Why - MarketBeat
5 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Investment Report: What are the future prospects of ProKidney Corp2026 Earnings Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
ProKidney (MEX:PROK) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
ProKidney hires chief commercial officer as key clinical test results near - Winston-Salem Journal
ProKidney names Greg Madison as chief commercial officer By Investing.com - Investing.com Australia
ProKidney appoints Greg Madison as chief commercial officer - TipRanks
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer - Bitget
ProKidney names Greg Madison as chief commercial officer - Investing.com
ProKidney expands senior leadership team with appointment of Greg Madison as chief commercial officer - marketscreener.com
Prokidney Expands Senior Leadership Team With Appointment Of Greg Madison As Chief Commercial Officer - TradingView
ProKidney (NASDAQ:PROK) Trading Down 7.6%Here's What Happened - MarketBeat
Q2 Earnings Forecast for ProKidney Issued By HC Wainwright - MarketBeat
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Sell: Does ProKidney Corp offer margin of safety2026 Outlook & Capital Efficiency Focused Ideas - baoquankhu1.vn
ProKidney A: Fundamental Analysis and Financial Ratings | PROK | KYG7S53R1049 - marketscreener.com
ProKidney (NASDAQ:PROK) Cut to Sell at Wall Street Zen - MarketBeat
ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results - The Business Journals
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Equities Analysts Set Expectations for ProKidney Q1 Earnings - MarketBeat
Guggenheim Sticks to Its Buy Rating for ProKidney (PROK) - The Globe and Mail
ProKidney’s Greensboro Facility Could Shield It From Looming Tariff Risks—But Time Is Short - Bitget
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability - TipRanks
ProKidney Makes Major Wager on U.S. Tariff Relief—Does Consistent Policy Support a $485M Risk? - Bitget
ProKidney ends fiscal 2025 with bigger loss, larger revenue stream - Winston-Salem Journal
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating - TipRanks
ProKidney (NASDAQ:PROK) Raised to "Strong-Buy" at Jefferies Financial Group - MarketBeat
ProKidney Corp. 2026 10-K Report: Business Overview, Clinical Trials, Risks, and Financial Highlights - Minichart
BofA reiterates ProKidney stock Underperform rating at $1 target By Investing.com - Investing.com South Africa
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BofA reiterates ProKidney stock Underperform rating at $1 target - Investing.com
ProKidney (NASDAQ:PROK) Releases Earnings Results - MarketBeat
ProKidney Reports Full Year 2025 Financial Results and Business Highlights - Bitget
PROK: FDA alignment, strong clinical progress, and cash runway into 2027 despite ongoing losses - TradingView
ProKidney (Nasdaq: PROK) details 2025 loss and cash runway into 2027 - Stock Titan
ProKidney (PROK) advances Phase 3 rilparencel program for diabetic CKD - Stock Titan
ProKidney’s High Cash Usage Dims Pipeline Hopes—Investors Brace for Funding Shortfall Before 2027 Results - bitget.com
ETF Watch: How volatile is ProKidney Corp stock2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Update: Why is ProKidney Corp stock going downRisk Management & AI Powered Market Entry Ideas - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Stock Price Down 4.7%Time to Sell? - MarketBeat
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):